StockNow
CalendarLog in
Other

Novo (NOVOB DC) entered a multi-target drug-discovery partnership with AI-focused Orbis Medicines worth up to USD 1.4bln to develop oral treatments for cardiometabolic diseases, Axios reports

StockNow breaking-news AI analysis

Novo partnered with Orbis Medicines in a deal worth up to $1.4 billion to discover oral cardiometabolic therapies, reflecting industry efforts to convert injectable biologics into oral treatments.

News detail

Axios says the deal reflects broader pharmaceutical efforts to convert biologic medicines that typically require injections or infusions into more convenient and potentially lower-cost oral therapies

1 stocks
NVONovo-Nordisk A/S$43.35Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump told Axios he is at a "critical juncture" regarding the war in Iran, weighing whether to launch massive new attacks or pursue a different path to end the conflict

Geopolitics

US approves visas for top Iranian leaders to attend UN high-level meeting even with sides at war, reports AP

Geopolitics

UK MTO says it received a report of a security incident in Strait of Hormuz 16 NM Northeast of Khasab, Oman